Zealand Pharma A/S (Zealand Pharma A/S) Inventory-to-Revenue : 0.36 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Zealand Pharma A/S's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.79 Mil. Zealand Pharma A/S's Revenue for the three months ended in Mar. 2024 was $2.20 Mil. Zealand Pharma A/S's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.36.

Zealand Pharma A/S's Inventory-to-Revenue for the quarter that ended in Mar. 2024 declined from Dec. 2023 (0.40) to Dec. 2023 (0.36)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Zealand Pharma A/S's Days Inventory for the three months ended in Mar. 2024 was 107.84.

Inventory Turnover measures how fast the company turns over its inventory within a year. Zealand Pharma A/S's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.85.

Zealand Pharma A/S Inventory-to-Revenue Historical Data

The historical data trend for Zealand Pharma A/S's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Inventory-to-Revenue Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.34

0.87

0.61

0.01

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory-to-Revenue	Get a 7-Day Free Trial															0.36	1.02	0.04	0.40	0.36

Competitive Comparison of Zealand Pharma A/S's Inventory-to-Revenue

For the Biotechnology subindustry, Zealand Pharma A/S's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Inventory-to-Revenue falls into.

Zealand Pharma A/S Inventory-to-Revenue Calculation

Zealand Pharma A/S's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0.183	+	1.161)	/	2 )	/	50.153
=	0.672					/	50.153
=	0.01

Zealand Pharma A/S's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

	Inventory-to-Revenue (Q: Mar. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Revenue (Q: Mar. 2024 )
=	( (1.161	+	0.425)	/	2 )	/	2.2
=	0.793					/	2.2
=	0.36

Zealand Pharma A/S (OTCPK:ZLDPF) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Zealand Pharma A/S's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0.793	/	0.671	*	365 / 4
	=	107.84

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Zealand Pharma A/S's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0.671	/	0.793
	=	0.85

Zealand Pharma A/S Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.